Ultragenyx Reports Third Quarter 2019 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ultragenyx Pharma (RARE) Misses Q3 EPS by 28c
November 5, 2019 4:53 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.96), $0.28 worse than the analyst estimate of ($1.68). Revenue for the quarter came in at $25.8 million versus the consensus estimate of $29.12 million.
Strong Crysvita® (burosumab) Launch Continues with Approximately 1,130 Patients on Reimbursed... More